blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3020718

EP3020718 - NOVEL PDE4 INHIBITOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.11.2019
Database last updated on 03.06.2024
FormerThe patent has been granted
Status updated on  23.11.2018
FormerGrant of patent is intended
Status updated on  19.08.2018
FormerExamination is in progress
Status updated on  30.07.2018
FormerGrant of patent is intended
Status updated on  03.07.2018
FormerExamination is in progress
Status updated on  23.02.2018
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Meiji Seika Pharma Co., Ltd.
4-16, Kyobashi 2-chome Chuo-ku
Tokyo 104-8002 / JP
[2016/20]
Inventor(s)01 / KIKUCHI, Chika
c/o Meiji Seika Pharma Co. Ltd.
760 Morooka-cho
Kohoku-ku
Yokohama-shi Kanagawa 222-8567 / JP
02 / TABATA, Yuji
c/o Meiji Seika Pharma Co. Ltd.
760 Morooka-cho
Kohoku-ku
Yokohama-shi Kanagawa 222-8567 / JP
03 / YAMAKAWA, Takeru
c/o Meiji Seika Pharma Co. Ltd.
760 Morooka-cho
Kohoku-ku
Yokohama-shi Kanagawa 222-8567 / JP
04 / MATSUHIRA, Takashi
c/o Meiji Seika Pharma Co. Ltd.
760 Morooka-cho
Kohoku-ku
Yokohama-shi Kanagawa 222-8567 / JP
05 / WATANABE, Naoko
c/o Meiji Seika Pharma Co. Ltd.
760 Morooka-cho
Kohoku-ku
Yokohama-shi Kanagawa 222-8567 / JP
06 / KUBOTA, Natsuki
c/o Meiji Seika Pharma Co. Ltd.
760 Morooka-cho
Kohoku-ku
Yokohama-shi Kanagawa 222-8567 / JP
07 / KANEDA, Kaori
c/o Meiji Seika Pharma Co. Ltd.
760 Morooka-cho
Kohoku-ku
Yokohama-shi Kanagawa 222-8567 / JP
 [2016/20]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2016/20]
Application number, filing date14823220.010.07.2014
[2016/20]
WO2014JP68435
Priority number, dateWO2013JP6890210.07.2013         Original published format: PCT/JP2013/068902
[2016/20]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015005429
Date:15.01.2015
Language:JA
[2015/02]
Type: A1 Application with search report 
No.:EP3020718
Date:18.05.2016
Language:EN
[2016/20]
Type: B1 Patent specification 
No.:EP3020718
Date:26.12.2018
Language:EN
[2018/52]
Search report(s)International search report - published on:JP15.01.2015
(Supplementary) European search report - dispatched on:EP18.11.2016
ClassificationIPC:C07D413/04, A61K31/496, A61P29/00, A61P43/00, C07D413/14, C07D417/14
[2016/20]
CPC:
C07D413/04 (EP,US); A61P29/00 (EP); A61P43/00 (EP);
C07D413/14 (EP,US); C07D417/14 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/20]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:NEUARTIGER PDE4-INHIBITOR[2016/20]
English:NOVEL PDE4 INHIBITOR[2016/20]
French:NOUVEL INHIBITEUR DE PDE4[2016/20]
Entry into regional phase20.01.2016Translation filed 
20.01.2016National basic fee paid 
20.01.2016Search fee paid 
20.01.2016Designation fee(s) paid 
20.01.2016Examination fee paid 
Examination procedure20.01.2016Examination requested  [2016/20]
30.05.2017Amendment by applicant (claims and/or description)
23.02.2018Despatch of a communication from the examining division (Time limit: M04)
06.06.2018Reply to a communication from the examining division
04.07.2018Communication of intention to grant the patent
24.07.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.08.2018Communication of intention to grant the patent
16.11.2018Fee for grant paid
16.11.2018Fee for publishing/printing paid
16.11.2018Receipt of the translation of the claim(s)
Opposition(s)27.09.2019No opposition filed within time limit [2019/49]
Fees paidRenewal fee
22.07.2016Renewal fee patent year 03
20.07.2017Renewal fee patent year 04
24.07.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.07.2014
AL26.12.2018
AT26.12.2018
CY26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
MK26.12.2018
MT26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
TR26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
IE10.07.2019
LU10.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
[2022/31]
Former [2021/34]HU10.07.2014
AL26.12.2018
AT26.12.2018
CY26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
MT26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
TR26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
IE10.07.2019
LU10.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
Former [2021/32]HU10.07.2014
AL26.12.2018
AT26.12.2018
CY26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
TR26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
IE10.07.2019
LU10.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
Former [2021/26]AL26.12.2018
AT26.12.2018
CY26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
TR26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
IE10.07.2019
LU10.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
Former [2020/36]AL26.12.2018
AT26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
TR26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
IE10.07.2019
LU10.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
Former [2020/25]AL26.12.2018
AT26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
TR26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
LU10.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
Former [2020/17]AL26.12.2018
AT26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
TR26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
Former [2020/14]AL26.12.2018
AT26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
Former [2020/13]AL26.12.2018
AT26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
Former [2019/48]AL26.12.2018
AT26.12.2018
CZ26.12.2018
DK26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
Former [2019/46]AL26.12.2018
AT26.12.2018
CZ26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
Former [2019/39]AL26.12.2018
CZ26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
IS26.04.2019
PT26.04.2019
Former [2019/37]AL26.12.2018
CZ26.12.2018
EE26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
NL26.12.2018
PL26.12.2018
RO26.12.2018
RS26.12.2018
SE26.12.2018
SM26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
PT26.04.2019
Former [2019/35]AL26.12.2018
CZ26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
NL26.12.2018
PL26.12.2018
RS26.12.2018
SE26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
PT26.04.2019
Former [2019/33]AL26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
NL26.12.2018
RS26.12.2018
SE26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
PT26.04.2019
Former [2019/30]AL26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
NL26.12.2018
RS26.12.2018
SE26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
Former [2019/26]AL26.12.2018
FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
RS26.12.2018
SE26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
Former [2019/25]FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
RS26.12.2018
SE26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
Former [2019/24]FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
SE26.12.2018
BG26.03.2019
NO26.03.2019
GR27.03.2019
Former [2019/23]FI26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
BG26.03.2019
NO26.03.2019
Former [2019/22]FI26.12.2018
LT26.12.2018
BG26.03.2019
NO26.03.2019
Former [2019/21]FI26.12.2018
LT26.12.2018
NO26.03.2019
Former [2019/20]LT26.12.2018
NO26.03.2019
Documents cited:Search[X]WO2008019372  (AMR TECHNOLOGY INC [US], et al) [X] 1 * step A;; example 138 *;
 [X]EP0806419  (MEIJI SEIKA KAISHA [JP], et al) [X] 5,8 * examples 9, 10, 13, 14; claims 1, 6 *;
 [A]WO0158896  (DARWIN DISCOVERY LTD [GB]) [A] 1-13 * claims 1, 8 *;
 [A]WO2009050242  (BOEHRINGER INGELHEIM INT [DE], et al) [A] 1-13 * examples 3, 10-12; claims 1, 17 *
International search[X]JP2010500368  (ALBANY MOLECULAR RESEARCH, INC.);
 [X]JPH1029987  (MEIJI SEIKA KAISHA, et al);
 [A]JPH06345744  (MEIJI SEIKA KAISHA, et al);
 [A]JP2003522771  (DARWIN DISCOVERY LTD.);
 [A]JP2009539848  (CORNERSTONE THERAPEUTICS INC.);
 [A]JP2009538909  (WYETH)
 [X]  - SATO, YASUO; ET AL., "Benzoxazole Derivatives as Novel 5-HT3 Receptor Partial Agonists in the Gut", JOURNAL OF MEDICINAL CHEMISTRY, (1998), vol. 41, no. 16, pages 3015 - 3021, XP002180160

DOI:   http://dx.doi.org/10.1021/jm9801004
 [X]  - YOSHIDA, SATOSHI; ET AL., "Orally Active Benzoxazole Derivative as 5-HT3 Receptor Partial Agonist for Treatment of Diarrhea- Predominant Irritable Bowel Syndrome", JOURNAL OF MEDICINAL CHEMISTRY, (2005), vol. 48, no. 22, pages 7075 - 7079, XP002437776

DOI:   http://dx.doi.org/10.1021/jm050209t
ExaminationEP0878194
by applicantJPH06345744
 JPH1029987
    - EXPERT OPIN. INVESTIG. DRUGS, (2002), vol. 11, pages 1 - 13
    - BRITISH JOURNAL OF PHARMACOLOGY, (2008), vol. 155, pages 308 - 315
    - BRITISH JOURNAL OF PHARMACOLOGY, (2011), vol. 163, pages 53 - 67
    - BRITISH JOURNAL OF PHARMACOLOGY, (2009), vol. 156, pages 534 - 544
    - AMADEU G; RICHARD S.R., EXPERT OPIN. THER. PATENTS, (201308), vol. 23, no. 8, pages 997 - 1016
    - BMC MEDICINE, (2013), vol. 11, page 96
    - DYKE H. J.; MONTANA J. G, EXPERT OPIN. INVESTIG. DRUGS, (2002), vol. 11, pages 1 - 13
    - SPINA D, BRITISH JOURNAL OF PHARMACOLOGY, (2008), vol. 155, pages 308 - 315
    - KLAUS F. R., BRITISH JOURNAL OF PHARMACOLOGY, (2011), vol. 163, pages 53 - 67
    - CORTIJO J ET AL., BRITISH JOURNAL OF PHARMACOLOGY, (2009), vol. 156, pages 534 - 544
    - AMADEU G; RICHARD S. R, EXPERT OPIN. THER. PATENTS, (201308), vol. 23, no. 8, pages 997 - 1016
    - KUMAR N. ET AL., BMC MEDICINE, (2013), vol. 11, page 96
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.